Evolution of Market Dynamics within Immunology after Biosimilar Introduction within Europe
Author(s)
Xin Q1, Keady S2, Bodin M3
1Biogen International HQ, Switzerland, Baar, ZG, Switzerland, 2Biogen International HQ, Switzerland, Baar, LON, Switzerland, 3Biogen International HQ, Switzerland, Baar, Switzerland
Presentation Documents
OBJECTIVES:
To understand the European evolution of market dynamics following the introduction of biosimilars within the immunology area.METHODS:
The report investigated 19 biologic molecules and 4 Janus kinase (JAK) inhibitors with approved immunology indications. Consumption was based on IQVIA MIDAS sales data (2017 to 2021). This reflected the first significant uptake of biosimilars in the immunology space in 2017. Molecule usage was measured in treatment days, derived from volume of standard units sold divided by average daily doses. To enable the comparison of molecule uptake across countries, a per-capita indicator treatment rate was used (dividing yearly total treatment days per molecule by population size).RESULTS:
Within immunology, average consumption of anti-TNF molecules increased by 35% from 0.51 treatment days/capita in 2017 to 0.68 treatment days/capita in 2021. Whilst the use of reference molecules has decreased by 31%, biosimilar use has increased by 346% from 0.09 treatment days/capita in 2017 to 0.39 treatment days/capita in 2021. Significant increases in usage of interleukin inhibitors and JAK inhibitors (168% and 1,906% respectively from 2017 to 2021) were also identified. In 2021, the countries with the highest treatment rates of all investigated molecules (Ireland, Norway, and Sweden) had an average of 2.22 treatment days/capita, whereas the lowest treatment rate countries (Belarus, Bosnia, and Poland) had 0.14 treatment days/capita (a 16-fold difference). Poland has one of the highest biosimilar penetrations (above 70% in 2021). However, the usage of biologics is still relatively low.CONCLUSIONS:
The use of approved immunological therapies has increased significantly since the introduction of biosimilars within Europe. However, there remains a substantial inequality, primarily between Eastern and Western countries. To mitigate inequalities, greater understanding of the combination of robust policies, risks and benefits of regionalized/centralized procurement models and promotion of sustainable pricing and reimbursement is required.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
OP1
Topic
Health Policy & Regulatory
Topic Subcategory
Reimbursement & Access Policy
Disease
Biologics & Biosimilars